secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001104659-23-069162
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed reports positive clinical data; plans pivotal trials H2 2023
-----------------------------------------------------------------------------

- BackBeat CNT showed 8.1 mmHg net reduction in 24-hour aSBP at 6 months and 17.5 mmHg oSBP reduction at 2 years.
- Virtue SAB in coronary ISR: 0.12 mm late lumen loss at 6 months, 2.8% target lesion failure at 1 year.
- Pivotal trials for BackBeat CNT and Virtue SAB intend to start in H2 2023.
- Medtronic collaboration: double-digit revenue share and $50M equity investment; Terumo: 10-15% royalty and $30M upfront.
- Target markets: >$10B (BackBeat CNT) and >$3B (Virtue SAB); strong balance sheet with committed investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923069162/0001104659-23-069162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465923069162/tm2318000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-069162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer